{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T05:17:12Z","timestamp":1780377432387,"version":"3.54.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002543","name":"Pusan National University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.clml.2025.06.006","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T11:18:59Z","timestamp":1749035939000},"page":"873-884","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-World Comparison of Carfilzomib, Lenalidomide, and Dexamethasone Versus Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed\/Refractory Multiple Myeloma: KMM2004 Study"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9468-8939","authenticated-orcid":false,"given":"Do Young","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Ki","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0484-2067","authenticated-orcid":false,"given":"Hyeon-Seok","family":"Eom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jongheon","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5878-8895","authenticated-orcid":false,"given":"Kihyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwai Han","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Yun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ja Min","family":"Byun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2341-4911","authenticated-orcid":false,"given":"Ji Hyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee Jeong","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9714-9615","authenticated-orcid":false,"given":"Sang Min","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Rok","family":"Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sungwoo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junglim","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Shin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4362-189X","authenticated-orcid":false,"given":"Hye Jin","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Hoon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3730-2777","authenticated-orcid":false,"given":"Sung-Nam","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3694-7031","authenticated-orcid":false,"given":"Ho-Jin","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.clml.2025.06.006_bib0001","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ajh.25791","article-title":"Multiple myeloma: 2020 update on diagnosis, risk-stratification and management","volume":"95","author":"Rajkumar","year":"2020","journal-title":"Am J Hematol"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2025.06.006_bib0002","first-page":"S3","article-title":"Current approaches to management of newly diagnosed multiple myeloma","volume":"97","author":"Goel","year":"2022","journal-title":"Am J Hematol"},{"issue":"9","key":"10.1016\/j.clml.2025.06.006_bib0003","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41408-020-00359-2","article-title":"Multiple myeloma current treatment algorithms","volume":"10","author":"Rajkumar","year":"2020","journal-title":"Blood Cancer J"},{"issue":"7","key":"10.1016\/j.clml.2025.06.006_bib0004","doi-asserted-by":"crossref","first-page":"867","DOI":"10.4065\/79.7.867","article-title":"Clinical course of patients with relapsed multiple myeloma","volume":"79","author":"Kumar","year":"2004","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"10.1016\/j.clml.2025.06.006_bib0005","first-page":"303","article-title":"Carfilzomib (Kyprolis): a novel proteasome inhibitor for relapsed and\/or refractory multiple myeloma","volume":"41","author":"Perel","year":"2016","journal-title":"PT"},{"issue":"2","key":"10.1016\/j.clml.2025.06.006_bib0006","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.clml.2025.06.006_bib0007","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s40262-018-0702-1","article-title":"Clinical Pharmacology of ixazomib: the first oral proteasome inhibitor","volume":"58","author":"Gupta","year":"2019","journal-title":"Clin Pharmacokinet"},{"issue":"17","key":"10.1016\/j.clml.2025.06.006_bib0008","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N Engl J Med"},{"issue":"57","key":"10.1016\/j.clml.2025.06.006_bib0009","doi-asserted-by":"crossref","first-page":"vii54","DOI":"10.1093\/rheumatology\/key109","article-title":"Randomized controlled trials and real-world data: differences and similarities to untangle literature data","volume":"57","author":"Monti","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"10.1016\/j.clml.2025.06.006_bib0010","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"26","key":"10.1016\/j.clml.2025.06.006_bib0011","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: a report from International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.06.006_bib0012","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1240966","article-title":"Definers and drivers of functional high-risk multiple myeloma: insights from genomic, transcriptomic, and immune profiling","volume":"13","author":"Banerjee","year":"2023","journal-title":"Front Oncol"},{"issue":"34","key":"10.1016\/j.clml.2025.06.006_bib0013","doi-asserted-by":"crossref","first-page":"e213","DOI":"10.3346\/jkms.2018.33.e213","article-title":"Real-world Evidence versus randomized controlled trial: Clinical Research Based on Electronic Medical Records","volume":"33","author":"Kim","year":"2018","journal-title":"J Korean Med Sci"},{"issue":"1","key":"10.1016\/j.clml.2025.06.006_bib0014","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s43441-020-00193-5","article-title":"Bridging the gap between RCTs and RWE through endpoint selection","volume":"55","author":"LoCasale","year":"2021","journal-title":"Ther Innov Regul Sci"},{"issue":"2","key":"10.1016\/j.clml.2025.06.006_bib0015","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1080\/19371910903070333","article-title":"Introduction: health of the health care system in Korea","volume":"25","author":"Kim","year":"2010","journal-title":"Soc Work Public Health"},{"issue":"2","key":"10.1016\/j.clml.2025.06.006_bib0016","first-page":"95","article-title":"The relative clinical efficacy of carfilzomib and ixazomib in MM_an indirect comparison","volume":"29","author":"Cantillana-Su\u00e1rez","year":"2019","journal-title":"Rev IL\u00b7ILAPHAR"},{"key":"10.1016\/j.clml.2025.06.006_bib0017","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.2147\/PPA.S183187","article-title":"Treatment of relapsed refractory multiple myeloma: Which new PI-based combination treatments do patients prefer?","volume":"12","author":"Wilke","year":"2018","journal-title":"Patient Prefer Adherence"},{"issue":"2","key":"10.1016\/j.clml.2025.06.006_bib0018","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s00277-017-3173-9","article-title":"Pooled analysis of the reports of carfilzomib\/ixazomib combinations for relapsed\/refractory multiple myeloma","volume":"97","author":"Xu","year":"2018","journal-title":"Ann Hematol"},{"issue":"3","key":"10.1016\/j.clml.2025.06.006_bib0019","first-page":"235","article-title":"Eligibility criteria and enrollment of a diverse racial and ethnic population in multiple myeloma clinical trials","volume":"142","author":"Kanapuru","year":"2023","journal-title":"J Blood"},{"issue":"14","key":"10.1016\/j.clml.2025.06.006_bib0020","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.clml.2025.06.006_bib0021","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.clml.2025.06.006_bib0022","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1200\/JCO.21.00972","article-title":"Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"39","author":"Richardson","year":"2021","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.clml.2025.06.006_bib0023","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1200\/JCO.2017.76.5032","article-title":"Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"36","author":"Siegel","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2025.06.006_bib0024","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12885-020-07732-1","article-title":"Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice","volume":"21","author":"Minarik","year":"2021","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.clml.2025.06.006_bib0025","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s00277-020-03981-z","article-title":"Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed\/refractory multiple myeloma","volume":"99","author":"Terpos","year":"2020","journal-title":"Ann Hematol"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2025.06.006_bib0026","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1182\/blood-2020-133807","article-title":"Real-life-setting effectiveness of ixazomib in combination with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: The remix study","volume":"136","author":"Clement-Filliatre","year":"2020","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2025.06.006_bib0027","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s12185-022-03479-6","article-title":"Real-world toxicity and effectiveness of ixazomib, lenalidomide, and dexamethasone in Korean patients with relapsed and\/or refractory multiple myeloma","volume":"117","author":"Lee","year":"2023","journal-title":"Int J Hematol"},{"issue":"1","key":"10.1016\/j.clml.2025.06.006_bib0028","first-page":"174","article-title":"Real-world use of carfilzomib combined with lenalidomide and dexamethasone in patients with multiple myeloma in Europe and Israel","volume":"4","author":"Leleu","year":"2023","journal-title":"EJ Haem"},{"issue":"2","key":"10.1016\/j.clml.2025.06.006_bib0029","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00277-020-04329-3","article-title":"Carfilzomib, lenalidomide, and dexamethasone in relapsed\/refractory multiple myeloma patients: The real-life experience of Rete Ematologica Pugliese (REP)","volume":"100","author":"Mele","year":"2021","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.clml.2025.06.006_bib0030","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/hon.2820","article-title":"A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed\/refractory multiple myeloma","volume":"39","author":"Rocchi","year":"2021","journal-title":"Hematol Oncol"},{"issue":"11","key":"10.1016\/j.clml.2025.06.006_bib0031","first-page":"3681","article-title":"Superior outcomes and high-risk features with carfilzomib, lenalidomide, and dexamethasone combination therapy for patients with relapsed and refractory multiple myeloma: Results of the multicenter KMMWP2201 study","volume":"109","author":"Lee","year":"2024","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.clml.2025.06.006_bib0032","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1007\/s00277-021-04534-8","article-title":"Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed\/refractory multiple myeloma (RRMM) in the US","volume":"100","author":"Davies","year":"2021","journal-title":"Ann Hematol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025002095?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025002095?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T01:10:47Z","timestamp":1763773847000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025002095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2152265025002095"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.06.006","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Comparison of Carfilzomib, Lenalidomide, and Dexamethasone Versus Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed\/Refractory Multiple Myeloma: KMM2004 Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}